Reference

Preparation and formulation of a crystalline b2 adrenergic receptor agonist, hydroxy(formamidohydroxyphenyl)ethylamine

Preparation and formulation of a crystalline b2 adrenergic receptor agonist, hydroxy(formamidohydroxyphenyl)ethylamine. Linsell, Martin S.; Jacobsen, John R.; Khossravi, Davar; Paborji, Mehdi; Zhang, Weijiang (Theravance, Inc., USA). PCT Int. Appl. WO 2004011416 A1 5 Feb 2004, 49 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C07C233-43. ICS: A61K031-165; A61P011-00; C07C209-16. APPLICATION: WO 2003-US23214 25 Jul 2003. PRIORITY: US 2002-PV398678 26 Jul 2002; US 2002-PV398928 26 Jul 2002. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 25 The invention provides formulations for the administration of a cryst. salt form of a novel b2 adrenergic receptor agonist. Methods of using the cryst. salt form to treat diseases assocd. with b2 adrenergic receptor activity, and processes useful for prepg. such a cryst. compd. are disclosed. Thus, an q. 201677-59-0 and 77-92-9 which are cas registry numbers of chemicals are mentioned. aerosol formulation contained a hydroxy(formamidohydroxyphenyl)ethylamine deriv. 0.1755, citric acid 2.10, Tween-80 0.05, 1N NaOH qs to pH 5.0, and 0.9% NaCl soln. qs to 1 g. .